<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893774</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2014-10</org_study_id>
    <secondary_id>2014-A01675-42</secondary_id>
    <nct_id>NCT02893774</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncer</brief_title>
  <acronym>ELCCA-II</acronym>
  <official_title>Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generally, French studies concerned with the quality of life of cancer patients focus on the
      period of treatment (up to 2 years post diagnosis). However, studies about quality of life
      &quot;after&quot; cancer are relatively rare (= long-term quality of life, or from 5 years post
      diagnosis). These studies mainly concern the most common cancers (breast and prostate).

      Or changes in quality of life after treatment could be different depending on the type of
      cancer. In addition, there is a significant influence of sociodemographic variables on the
      quality of life in remission.

      Similarly using remote diagnostics, quality of life questionnaires related to health, must be
      reassessed because too often developed for situations in process.

      Based on these findings, &quot;ELCCA II&quot; study proposes to study for five years, the evolution of
      the impacts of two types of cancer (breast and melanoma) on quality of life (overall and
      related to the subjective health), socioeconomic status, and behavioral and emotional
      dimensions (post-traumatic development, coping, anxiety-depression) of those treated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>long term evolution of quality of life for patient with breast cancer or melanoma</measure>
    <time_frame>5 years after initial cancer diagnostics</time_frame>
    <description>The evolution of quality of life will be assess with standardized quality of life questionnaire</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>cancer quality of life</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality of life assessment</intervention_name>
    <description>All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.
Those assessment will use standardized quality of life questionnaire :
QLQ-C30
SWLS (Satisfaction with Life Scale)
PTGI (Post-Traumatic Growth Inventory)
HADS (Hospital Anxiety and Depression Scale)
Brief COPE
MHLCS (Multidimensional Health Locus of Control Scale)</description>
    <arm_group_label>cancer quality of life</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of cancer (breast or melanoma) since less than 1 month

          -  no metastasis

          -  Inform Consent Form signed

        Exclusion Criteria:

          -  severe psychiatric disorder (depression, psychosis, etc.)

          -  addictive pathology

          -  longtime antidepressant treatment (&gt; 3 months)

          -  Patient pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CAMPONE Mario, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BONNAUD Angélique</last_name>
    <phone>+33 2 40 67 99 00</phone>
    <email>angelique.bonnaud@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PACTEAU Valérie</last_name>
    <phone>+33 2 40 67 99 00</phone>
    <email>valerie.pacteau@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO René Gauducheau</name>
      <address>
        <city>Nantes - St herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BONNAUD Angélique</last_name>
      <phone>+33 2 40 67 99 00</phone>
      <email>angelique.bonnaud@ico.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

